Half-Year Results: Bigger Losses, Thinner Cash, Deal Still Pending
Seed Capital Solutions has posted an unaudited half-year loss of £524,000 for the six months to 31 December 2025, compared with £158,000 in the same period last year. Other operating income was £33,600, offset by administrative expenses of £557,600. Basic loss per share came in at 0.28p (HY24: 0.08p).
The cash position is the headline: just £14,700 in the bank at period end, down from £211,400 at 30 June 2025 and £310,700 a year ago. Meanwhile, trade and other payables rose to £500,200, tipping the balance sheet into a net liabilities position of £398,100 (30 June 2025: net assets of £125,900).
The Company says it is still working with advisers and its sponsor to finalise documentation for the proposed acquisition of Cuarta Dimension Medica SL (4DM), to be paid for in new shares, with a subsequent readmission of Seed Capital’s shares to trading. If completed, the enlarged group would focus on AI-driven diagnostics in the veterinary market, with scope to expand into wider healthcare.
Key Numbers Investors Should Know
| Metric | HY to 31 Dec 2025 | Comparatives |
|---|---|---|
| Net loss | £524,000 | HY24: £158,000; FY25: £420,400 |
| Other operating income | £33,600 | HY24: £Nil; FY25: £111,400 |
| Administrative expenses | £557,600 | HY24: £158,000; FY25: £445,400 |
| Loss per share | 0.28p | HY24: 0.08p; FY25: 0.23p |
| Cash at bank | £14,700 | HY24: £310,700; 30 Jun 2025: £211,400 |
| Trade and other payables | £500,200 | HY24: £61,700; 30 Jun 2025: £217,900 |
| Net (liabilities)/assets | £(398,100) | HY24: £301,900; 30 Jun 2025: £125,900 |
| Operating cash outflow | £196,700 | HY24: £207,400 |
| Shares in issue | 185,406,000 | No change |
| Warrants outstanding | 25,313,532 @ 1.041p | Vested, five-year life |
Cash Runway: Why Liquidity Is the Immediate Concern
Operating cash outflow was £196,700 over six months, roughly £32,800 per month. Against a 31 December cash balance of £14,700, the historical burn rate implies a very short runway at the reporting date.
The Company notes no events after the reporting date that require disclosure. There is no mention of fresh funding being raised – not disclosed. With payables at £500,200 and net liabilities of £398,100, liquidity is clearly tight. In my view, completion of the 4DM deal or a bridging finance solution looks essential in the near term.
Proposed 4DM Acquisition: The Strategic Bet on AI Veterinary Diagnostics
Seed Capital is a shell targeting socially conscious, tech-led assets. The chosen target, 4DM, would transform the business into an AI-driven diagnostics company focused initially on the veterinary sector, with potential to expand into broader healthcare. The consideration is in new shares, meaning shareholders should expect dilution on completion.
A successful reverse takeover followed by readmission to the London Stock Exchange would give Seed a real operating business in a growth niche. In plain English: this is the make-or-break transaction. If it completes and the technology gains traction, there is a path to value creation. If it stalls, the Company must find another target or raise funds simply to keep the lights on.
Balance Sheet Reality: Net Liabilities and Growing Payables
The balance sheet has deteriorated materially since June. Total assets fell to £102,100, while payables climbed to £500,200. That swing has moved shareholders’ funds to a deficit of £398,100.
There were no new share issues in the period. However, 25.3 million warrants are outstanding with a weighted average exercise price of 1.041p. If exercised, they would inject cash and increase the share count, but exercise depends on market price being attractive for holders.
How the P&L Shifted: Costs Up, Losses Widen
Administrative expenses of £557,600 are significantly higher than both the prior half-year (£158,000) and the last full year (£445,400). Other operating income contributed £33,600, but not nearly enough to offset the ramp-up in costs. The bottom line: the half-year loss of £524,000 already exceeds the loss for the whole of FY25.
Loss per share rose to 0.28p, with the weighted average share count unchanged at 185.4 million. There is no tax charge.
Governance and Related Parties: What’s Disclosed
Related party fees in the half-year were modest in absolute terms: £6,000 invoiced by the CFO via Danmar Management Limited, and £37,500 by the CEO via a wholly-owned service company. The Board reaffirmed responsibility for the interim statements, prepared under IAS 34 (the accounting standard for interim reporting).
Risks the Board Calls Out (and What They Mean)
- Acquisition risk – The 4DM deal may not complete. If it fails, Seed must find a new target on acceptable terms.
- Liquidity risk – Due diligence and deal costs drain cash without a guarantee of success. With £14,700 in cash at period end, this is front and centre.
- Funding risk – Additional equity or other financing may be needed but not secured. Translation: potential dilution or deal delay.
- Implementation risk – Even if the deal completes, integration or underperformance could hit returns.
In short, all roads lead back to the 4DM transaction and funding. The Company’s experience and network are cited as mitigants, but outcomes depend on market conditions and approvals.
What Could Move the Share Price Next
- Formal completion terms and a clear timetable for readmission to trading.
- Details on 4DM’s commercial traction, customers, and regulatory pathway – not disclosed in this RNS.
- Funding news: bridge finance, placing, or warrant exercises to shore up liquidity.
- Any change in payables or confirmation of payment schedules with creditors.
Jargon Buster
- Readmission – When a company’s shares are admitted back to trading on the exchange after a significant transaction.
- Shell company category – A listing segment for companies that are essentially cash shells seeking an acquisition.
- Warrants – Rights to subscribe for new shares at a fixed price within a set timeframe. Exercise is usually price dependent.
Josh’s Take: High Risk Until the Deal Lands
This update is dominated by the balance sheet squeeze. Cash was £14,700 at year-end, operating cash burn averaged around £32,800 per month, and payables have ballooned. The Company is candid about acquisition, liquidity and funding risks. That transparency is welcome, but it underscores the urgency.
The upside case hangs on completing the 4DM acquisition and proving the AI diagnostics thesis in veterinary care. If the documentation finalises swiftly, funding is secured, and readmission follows, Seed Capital could pivot from shell to growth story. Until then, this is a financing-and-execution trade. Expect volatility, watch for funding news, and treat timelines as the key catalyst.
